volume 2, issue 8, PS446-S447 2007
DOI: 10.1097/01.jto.0000283370.40468.55
View full text
|
|
Share

Abstract: ERBB3 interacts with EGFR and is expressed in EGFR TKI sensitive NSCLC cell lines and may represent a poor prognostic marker in NSCLC. In this study we correlated the activity of the HDAC inhibitor vorinostat in NSCLC cell lines with ERBB3 expression and evaluated the synergistic effect of vorinostat with gefitinib. Further, we evaluated the interaction of ERBB3 and E-cadherin and their effect on response to gefitinib. Methods: Apoptosis: cell lines were incubated in control medium or in the presence of variou…

Expand abstract

Search citation statements

Order By: Relevance

Citation Types

0
0
0

Paper Sections

0
0
0
0
0

Publication Types

0
0
0
0

Relationship

0
0

Authors

Journals